HRP20170334T1 - Spojevi enedina, njihovi konjugati, primjene i metode - Google Patents
Spojevi enedina, njihovi konjugati, primjene i metode Download PDFInfo
- Publication number
- HRP20170334T1 HRP20170334T1 HRP20170334TT HRP20170334T HRP20170334T1 HR P20170334 T1 HRP20170334 T1 HR P20170334T1 HR P20170334T T HRP20170334T T HR P20170334TT HR P20170334 T HRP20170334 T HR P20170334T HR P20170334 T1 HRP20170334 T1 HR P20170334T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- unsubstituted
- substituted
- nhc
- image
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261598143P | 2012-02-13 | 2012-02-13 | |
| US201261653785P | 2012-05-31 | 2012-05-31 | |
| EP13704871.6A EP2814829B1 (en) | 2012-02-13 | 2013-02-08 | Enediyne compounds, conjugates thereof, and uses and methods therefor |
| PCT/US2013/025247 WO2013122823A1 (en) | 2012-02-13 | 2013-02-08 | Enediyne compounds, conjugates thereof, and uses and methods therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170334T1 true HRP20170334T1 (hr) | 2017-04-21 |
Family
ID=47722570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170334TT HRP20170334T1 (hr) | 2012-02-13 | 2013-02-08 | Spojevi enedina, njihovi konjugati, primjene i metode |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US8709431B2 (enExample) |
| EP (1) | EP2814829B1 (enExample) |
| JP (1) | JP6113194B2 (enExample) |
| KR (1) | KR101660146B1 (enExample) |
| CN (1) | CN104220441B (enExample) |
| AR (1) | AR089972A1 (enExample) |
| AU (1) | AU2013221873B2 (enExample) |
| BR (1) | BR112014019990A8 (enExample) |
| CA (1) | CA2864420C (enExample) |
| CL (1) | CL2014002096A1 (enExample) |
| CO (1) | CO7061078A2 (enExample) |
| CY (1) | CY1118899T1 (enExample) |
| DK (1) | DK2814829T3 (enExample) |
| EA (1) | EA027925B1 (enExample) |
| ES (1) | ES2615268T3 (enExample) |
| HK (1) | HK1204326A1 (enExample) |
| HR (1) | HRP20170334T1 (enExample) |
| HU (1) | HUE033704T2 (enExample) |
| IL (1) | IL233965B (enExample) |
| LT (1) | LT2814829T (enExample) |
| MX (1) | MX350539B (enExample) |
| PE (1) | PE20141791A1 (enExample) |
| PL (1) | PL2814829T3 (enExample) |
| PT (1) | PT2814829T (enExample) |
| RS (1) | RS55763B1 (enExample) |
| SG (1) | SG11201404667XA (enExample) |
| SI (1) | SI2814829T1 (enExample) |
| SM (1) | SMT201700137T1 (enExample) |
| TW (1) | TW201336851A (enExample) |
| WO (1) | WO2013122823A1 (enExample) |
| ZA (1) | ZA201406723B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| MX368016B (es) * | 2013-08-14 | 2019-09-13 | Univ Rice William M | Derivados de uncialamicina, métodos de sintesis y su uso como agentes antitumor. |
| CN115322253A (zh) | 2014-03-20 | 2022-11-11 | 百时美施贵宝公司 | 稳定化的基于纤连蛋白的支架分子 |
| HUE050596T2 (hu) | 2014-11-21 | 2020-12-28 | Bristol Myers Squibb Co | Antitestek CD73 ellen és azok felhasználásai |
| LT3221346T (lt) | 2014-11-21 | 2020-11-10 | Bristol-Myers Squibb Company | Antikūnai, apimantys modifikuotas sunkiosios grandinės pastoviąsias sritis |
| ES2822990T3 (es) | 2014-11-25 | 2021-05-05 | Bristol Myers Squibb Co | Novedosos polipéptidos de unión a PD-L1 para obtención de imágenes |
| WO2016112282A1 (en) * | 2015-01-08 | 2016-07-14 | The Scripps Research Institute | Anticancer drug candidates |
| CN107406496A (zh) | 2015-03-10 | 2017-11-28 | 百时美施贵宝公司 | 可通过转谷氨酰胺酶缀合的抗体和由其制备的缀合物 |
| UY36687A (es) | 2015-05-29 | 2016-11-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Anticuerpos contra ox40 y sus usos |
| ES2809125T3 (es) | 2015-09-23 | 2021-03-03 | Bristol Myers Squibb Co | Moléculas de armazón a base de fibronectina de unión a glipicano-3 |
| EP3165532B1 (en) | 2015-11-03 | 2018-12-19 | Industrial Technology Research Institute | Auristatin derivatives, linker-drugs and ligand-drug conjugates |
| JP2019505575A (ja) | 2015-12-21 | 2019-02-28 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 部位特異的な結合のための変異型抗体 |
| IL295230A (en) | 2016-03-04 | 2022-10-01 | Bristol Myers Squibb Co | Combination therapy with anti-cd73 antibodies |
| CN106267188B (zh) * | 2016-08-15 | 2025-06-17 | 深圳大学 | 小分子免疫激动剂偶联pd-1抗体的新型抗体及其在抗肿瘤中的应用 |
| US20190218294A1 (en) | 2016-09-09 | 2019-07-18 | Bristol-Myers Squibb Company | Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
| MX2019013132A (es) | 2017-05-25 | 2020-01-27 | Bristol Myers Squibb Co | Anticuerpos que comprenden regiones constantes pesadas modificadas. |
| WO2019110725A1 (en) * | 2017-12-06 | 2019-06-13 | Synaffix B.V. | Enediyne conjugates |
| CN110183659B (zh) * | 2018-02-21 | 2022-04-26 | 香港科技大学 | 含有杂环的聚合物、其制备方法及其应用 |
| US20220106400A1 (en) | 2018-11-28 | 2022-04-07 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
| BR112021010060B1 (pt) | 2018-11-30 | 2024-03-12 | Bristol-Myers Squibb Company | Anticorpo que compreende uma extensão c-terminal de cadeia leve que contém glutamina, conjugados do mesmo, e método de preparação de conjugados |
| WO2020123425A2 (en) | 2018-12-12 | 2020-06-18 | Bristol-Myers Squibb Company | Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses |
| SG11202112856QA (en) * | 2019-05-22 | 2021-12-30 | Univ Texas | Functionalized gold carbene naphthoquinone complexes for use in the treatment of cancer |
| US20240377413A1 (en) | 2019-09-16 | 2024-11-14 | Bristol-Myers Squibb Company | Dual capture method for analysis of antibody-drug conjugates |
| CA3223936A1 (en) | 2021-06-28 | 2023-01-05 | Ronald Christiaan Elgersma | Conjugates comprising phosphoantigens and their use in therapy |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US5144011A (en) | 1981-06-26 | 1992-09-01 | Boston University | Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers |
| US4631190A (en) | 1981-06-26 | 1986-12-23 | Shen Wei C | Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4698420A (en) | 1985-02-25 | 1987-10-06 | Xoma Corporation | Antibody hybrid molecules and process for their preparation |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5281710A (en) * | 1990-08-01 | 1994-01-25 | The Scripps Research Institute | Dynemicin analogs: synthesis, methods of preparation and use |
| US5162330A (en) * | 1990-11-05 | 1992-11-10 | Bristol-Myers Squibb Co. | Dynemicin c antibiotic, its triacetyl derivative and pharmaceutical composition containing same |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US6955811B2 (en) | 1997-11-07 | 2005-10-18 | Trillium Therapeutics Inc. | Methods of inhibiting immune response suppression by administering antibodies to OX-2 |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US7129261B2 (en) | 2001-05-31 | 2006-10-31 | Medarex, Inc. | Cytotoxic agents |
| US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| CN1638800A (zh) | 2002-01-09 | 2005-07-13 | 米德列斯公司 | 抗cd30的人类单克隆抗体 |
| EP2261244A3 (en) | 2003-04-15 | 2011-02-23 | Glaxosmithkline LLC | Human il-18 substitution mutants and their conjugates |
| MXPA06000798A (es) | 2003-07-22 | 2006-04-07 | Schering Ag | Anticuerpos de rg1 y usos de los mismos. |
| WO2005051976A2 (en) | 2003-11-20 | 2005-06-09 | Ansata Therapeutics, Inc. | Protein and peptide ligation processes and one-step purification processes |
| US8170637B2 (en) * | 2008-05-06 | 2012-05-01 | Neurosky, Inc. | Dry electrode device and method of assembly |
| EP1718667B1 (en) | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| WO2005112919A2 (en) | 2004-05-19 | 2005-12-01 | Medarex, Inc. | Self-immolative linkers and drug conjugates |
| RU2402548C2 (ru) | 2004-05-19 | 2010-10-27 | Медарекс, Инк. | Химические линкеры и их конъюгаты |
| KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
| US7714016B2 (en) | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
| ES2720160T3 (es) | 2005-05-09 | 2019-07-18 | Ono Pharmaceutical Co | Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas |
| AU2006262232A1 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | CD19 antibodies and their uses |
| KR20080056167A (ko) | 2005-09-26 | 2008-06-20 | 메다렉스, 인코포레이티드 | 씨디70에 대한 인간 모노크로날 항체 |
| EP1940470B1 (en) | 2005-09-26 | 2013-04-17 | Medarex, Inc. | Antibody-drug conjugates and their use |
| WO2007038868A2 (en) * | 2005-10-03 | 2007-04-12 | The University Of British Columbia | Novel enediyne compound and uses thereof |
| EA015324B1 (ru) | 2005-10-26 | 2011-06-30 | Медарекс, Инк. | Способы и соединения для получения аналогов сс-1065 |
| CA2627190A1 (en) | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
| NZ568015A (en) | 2005-12-08 | 2012-03-30 | Medarex Inc | Human monoclonal antibodies to O8E |
| DK1957539T3 (da) | 2005-12-08 | 2013-05-06 | Medarex Inc | Humane monoklonale antistoffer til proteintyrosinkinase 7 (ptk7) og deres anvendelse |
| KR100869414B1 (ko) | 2005-12-13 | 2008-11-21 | 야마하 가부시키가이샤 | 건반식 음판 타악기용의 음판 및 그 제조방법, 음판타악기의 음원 유닛 및 건반식 타악기 |
| NZ574673A (en) | 2006-09-08 | 2012-02-24 | Ambrx Inc | Site specific incorporation of non-natural amino acids by vertebrate cells |
| BRPI0717902A2 (pt) | 2006-12-01 | 2013-10-29 | Medarex Inc | "anticorpo monoclonal humano isolado, composição, conjugado anticorpo-molécula parceria, imunoconjugado, molécula de ácido nucléico isolada, vetor de expressão, célula hospedeira, método para prepar um anticorpo anti-cd22, método para inibir o desenvolvimento de uma célula tumoral que expressa cd22 e método para tratar uma doença inflamatória ou autoimuneem um indivíduo" |
| UY30776A1 (es) | 2006-12-21 | 2008-07-03 | Medarex Inc | Anticuerpos cd44 |
| TWI412367B (zh) | 2006-12-28 | 2013-10-21 | Medarex Llc | 化學鏈接劑與可裂解基質以及其之綴合物 |
| CA2678514A1 (en) | 2007-02-21 | 2008-08-28 | Medarex, Inc. | Chemical linkers with single amino acids and conjugates thereof |
| EP2185188B1 (en) | 2007-08-22 | 2014-08-06 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
| CA2700860C (en) | 2007-10-01 | 2016-07-19 | Jonathan A. Terrett | Human antibodies that bind mesothelin, and uses thereof |
| EP2391714B2 (en) | 2009-01-30 | 2019-07-24 | Whitehead Institute for Biomedical Research | Methods for ligation and uses thereof |
-
2013
- 2013-02-08 SG SG11201404667XA patent/SG11201404667XA/en unknown
- 2013-02-08 TW TW102105196A patent/TW201336851A/zh unknown
- 2013-02-08 DK DK13704871.6T patent/DK2814829T3/en active
- 2013-02-08 HK HK15104893.3A patent/HK1204326A1/xx unknown
- 2013-02-08 CN CN201380019853.3A patent/CN104220441B/zh not_active Expired - Fee Related
- 2013-02-08 EP EP13704871.6A patent/EP2814829B1/en active Active
- 2013-02-08 PE PE2014001257A patent/PE20141791A1/es not_active Application Discontinuation
- 2013-02-08 LT LTEP13704871.6T patent/LT2814829T/lt unknown
- 2013-02-08 HR HRP20170334TT patent/HRP20170334T1/hr unknown
- 2013-02-08 CA CA2864420A patent/CA2864420C/en not_active Expired - Fee Related
- 2013-02-08 SI SI201330469T patent/SI2814829T1/sl unknown
- 2013-02-08 AR ARP130100431A patent/AR089972A1/es unknown
- 2013-02-08 ES ES13704871.6T patent/ES2615268T3/es active Active
- 2013-02-08 KR KR1020147025070A patent/KR101660146B1/ko not_active Expired - Fee Related
- 2013-02-08 JP JP2014556700A patent/JP6113194B2/ja not_active Expired - Fee Related
- 2013-02-08 WO PCT/US2013/025247 patent/WO2013122823A1/en not_active Ceased
- 2013-02-08 EA EA201491447A patent/EA027925B1/ru not_active IP Right Cessation
- 2013-02-08 PL PL13704871T patent/PL2814829T3/pl unknown
- 2013-02-08 MX MX2014009234A patent/MX350539B/es active IP Right Grant
- 2013-02-08 HU HUE13704871A patent/HUE033704T2/en unknown
- 2013-02-08 AU AU2013221873A patent/AU2013221873B2/en not_active Ceased
- 2013-02-08 PT PT137048716T patent/PT2814829T/pt unknown
- 2013-02-08 RS RS20170239A patent/RS55763B1/sr unknown
- 2013-02-08 BR BR112014019990A patent/BR112014019990A8/pt not_active Application Discontinuation
- 2013-02-08 SM SM20170137T patent/SMT201700137T1/it unknown
- 2013-02-11 US US13/764,226 patent/US8709431B2/en active Active
-
2014
- 2014-03-10 US US14/203,118 patent/US9156850B2/en active Active
- 2014-08-06 IL IL233965A patent/IL233965B/en active IP Right Grant
- 2014-08-07 CL CL2014002096A patent/CL2014002096A1/es unknown
- 2014-08-28 CO CO14189746A patent/CO7061078A2/es unknown
- 2014-09-12 ZA ZA2014/06723A patent/ZA201406723B/en unknown
-
2017
- 2017-03-03 CY CY20171100285T patent/CY1118899T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170334T1 (hr) | Spojevi enedina, njihovi konjugati, primjene i metode | |
| JP2015508074A5 (enExample) | ||
| JP2018503639A5 (enExample) | ||
| JP2018502131A5 (enExample) | ||
| HRP20160164T1 (hr) | Citotoksiäśni derivati benzodiazepina | |
| NZ701478A (en) | Pyrrolobenzodiazepines | |
| CY1122789T1 (el) | Συνδετες για συζευγματα αντισωματων-φαρμακων | |
| HRP20201446T1 (hr) | Konjugati analoga cc-1065 i bifunkcionalnih veznika | |
| IL261259A (en) | Compounds for positron emission tomography | |
| HRP20211640T1 (hr) | Konjugati pirolobenzodiazepin - protutijelo | |
| JP2017528467A5 (enExample) | ||
| JP2017503777A5 (enExample) | ||
| RU2010135836A (ru) | Композиции и способы лечения рака | |
| GEP20237497B (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
| NZ710745A (en) | Pyrrolobenzodiazepines and conjugates thereof | |
| HRP20210979T1 (hr) | Konjugati pirolobenzodiazepin-protutijelo | |
| EA200971085A1 (ru) | Аналоги гетероариламидов | |
| JP2018516243A5 (enExample) | ||
| BR112014029972A2 (pt) | reagentes de conjugação | |
| JP2018502902A5 (enExample) | ||
| DE502008001409D1 (de) | Bisamid-zinkbasen | |
| MX377208B (es) | Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos. | |
| JP2019524845A5 (enExample) | ||
| JPWO2020236825A5 (enExample) | ||
| JP2018518506A5 (enExample) |